Drug intelligence / Profile preview

NST-25

Development stage: Preclinical
Lead developer: Novasenta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NST-25 is a preclinical-stage monoclonal antibody developed by Novasenta that targets CD161 (also known as KLRB1). CD161 is an inhibitory receptor expressed on various immune cells, including T cells and Natural Killer (NK) cells. NST-25 is designed with a dual mechanism of action: it blocks CD161 signaling to prevent immune suppression and depletes CD161-expressing cells that contribute to disease pathology. The program is currently being investigated for the treatment of inflammatory diseases and hematological (heme) cancers.

Other names: NST-25NST25NST 25

Targets

KLRB1 (C-type lectin-like receptor CD161)

Beyond the preview

Go deeper on NST-25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST-25.

Explore the full profile